Posts by admin
36 – Conf. Univ. Dr. Habil. Smaranda Belciug – I.A. în cancer – posibilități și perspective
35 – Asist. Prof. Dr. Radu Minea – Integrine/dizintegrine, o nouă speranță în tratament …
34 – Asist. Prof. Dr. Radu Minea – Glioblastomul – mai este loc de imbunatatiri in tratament?
33 – Psiholog Dr. Violeta Popa – Complianța terapeutică în comunicarea veștilor rele în oncologie
37 – Conf. Univ. Dr. Ruslan Baltaga – Actualitati oncologice in Republica Moldova
36 – Conf. Univ. Dr. Habil. Smaranda Belciug – I.A. in cancer – posibilitati si perspective
35 – Asist. Prof. Dr. Radu Minea – „Integrine/dizintegrine, o nouă speranță in tratament …?
34 – Asist. Prof. Dr. Radu Minea – „Glioblastomul – mai este loc de imbunatatiri in tratament?
33 – Psiholog Dr. Violeta Popa – Complianta terapeutica in comunicarea vestilor rele in oncologie
32 – Cristian Papazoglu – Cancerele genito-urinare: cauze, simptome, tratamen
31 – Daniela Bota – „Unde suntem azi in neuro-oncologie?”
30 – Dr. Bogdan Fetica – „Rolul patologului și al patologiei în diagnosticul de cancer”
32 – Asist. Prof. Dr. Cristian Papazoglu – Cancerele genito urinare: cauze, simptome, tratament
31 – Prof. Dr. Daniela Bota – „Unde suntem azi in neuro-oncologie?”
30 – Dr. Bogdan Fetica – „Rolul patologului și al patologiei în diagnosticul de cancer”
29 – Horia Sîrbu – Chirurgia toracică în oncologie
28 – Răzvan Curcă – Despre îngrijirea paliativă și comunicarea veștilor proaste
27 – Dr. Razvan Curca – Ingrijirea pacientilor oncologici
29 – Horia Sîrbu – Chirurgia toracică în oncologie
28 – Răzvan Curcă – Despre ingrijirea paliativa si comunicarea vestilor proaste
27 – Dr. Răzvan Curcă – Îngrijirea pacienților oncologici
26 Prof. univ. dr. Gheorge Peltecu – Ginecologia Oncologica – Cancerul Cervical
25 Prof. univ. dr. Gheorge Peltecu – Ginecologia Oncologica – Cancerul Ovarian
24 Prof. univ. dr. Gheorge Peltecu – Ginecologia Oncologica, istoria unui pionierat
23 Conf. univ. dr. Claudia Burz – Integrarea serviciilor de îngrijire paliativă
Lansare cărți „Metafizica Celulei” și „Cioran și tămăduirea disperării” – dr. Mircea Leabu
22 Prof. Univ. Dr. Ioana-Berindan Neagoe – Profilul genomic în oncologia medicală …
21 Dr. Mircea Leabu – Metafizica Celulei – De la potențial la real sau de la numenal la fenomenal
18 Sub amenintarea cancerului. Fara tabuuri, despre sănătatea sânilor – dna. Oana Arghir
17 Exozomii, posibile solutii in oncologie – dr. Irina Matei, Ph.D.
14 Al 7 -lea Simpozion de Oncologie Translațională Personalizată pentru combaterea cancerului
13 Part 2 – Povestea unei supravietuitoare a cancerului de san
12 Part 1 – Povestea unei supravietuitoare a cancerului de san
11 Tratamentul cancerului in sistemul medical din Germania – Prof. Dr. med. Dr. h.c. Pompiliu Piso
10 Cancerul de sân part. 2/2 – Dr. Dragos Median
09 Cancerul de sân part. 1/2 – Dr. Dragos Median
08 Consilierul-navigator medical, calauza in sistemul medical romanesc p2/2 – dna. Alina Comanescu
07 Consilierul-navigator medical, calauza in sistemul medical romanesc p1/2 dna. Alina Comanescu
26 – Prof. univ. dr. Gheorge Peltecu – Ginecologia Oncologica – Cancerul Cervical
25 – Prof. univ. dr. Gheorge Peltecu – Ginecologia Oncologica – Cancerul Ovarian
10 Consiliere Psihologică – nutriţie (2)- Prof. dr. Mihaela Minulescu, Dr. Irina Mateieș
Lansare cărți „Metafizica Celulei” și „Cioran și tămăduirea disperării” – dr. Mircea Leabu
24 – Prof. univ. dr. Gheorge Peltecu – …Ginecologia Oncologica, istoria unui pionierat
23 – Conf. univ. dr. Claudia Burz – Integrarea serviciilor de îngrijire paliativă
22 – Prof. Univ. Dr. Ioana-Berindan Neagoe – „Profilul genomic în oncologia medicală. Ce am învatat
21 – Dr. Mircea Leabu – Metafizica Celulei – De la potențial la real sau de la numenal la fenomenal
20 – Dr. Dan Duda, DMD, PhD – ”Tratamentul cancerului de ficat”
19 – Dr. Mirela Roman – ”Chirurgia în tratamentul cancerului de sân”
18 – ”Sub amenințarea cancerului. Fără tabuuri, despre sănătatea sânilor” – dna. Oana Arghir
17 – Dr. Irina Matei, Ph.D. – ”Exozomii, posibile soluții în oncologie”
16 – Dr. Alina Miruna Grecea – ”Noile tratamente în cancerul de sân”
15 – Concluzii – Al 7-lea Simpozion de Oncologie Translațională Pers de Combatere a Cancerului 2023
14 – Al 7 lea Simpozion de Oncologie Translațională Personalizată pentru combaterea cancerului-2023
13 – Întâlnirile STOP Cancer „Part 2 – Povestea unei supravietuitoare a cancerului”
12 – Întâlnirile STOP Cancer „Part 1 – Povestea unei supravietuitoare a cancerului”
11 – Întâlnirile STOP Cancer „Trat. cancerului în sist. med. din Germania”
10 – Întâlnirile STOP Cancer „Cancerul de sân part. 2/2”
09 – Întâlnirile STOP Cancer „Cancerul de sân part. 1/2”
08 – Întâlnirile STOP Cancer „Consilierul-navigator medical, part. II-a”
07 – Întâlnirile STOP Cancer „Consilierul-navigator medical”
06 Cancere: particularități, abordare și tratament
06 – Întâlnirile STOP Cancer „Cancere: particularități, abordare și tratament
05 Cancerul de prostată
05 – Întâlnirile STOP Cancer „Cancerul de prostată”
04 „Radioterapia cancerelor O.R.L.”
04 – Întâlnirile STOP Cancer „Radioterapia cancerelor O.R.L.”
Întâlnirile STOP Cancer „Inițiativa Stop Cancer (3)”
03 – Întâlnirile STOP Cancer „Inițiativa Stop Cancer (3)”
Întâlnirile STOP Cancer „Inițiativa Stop Cancer (2)
02 – Întâlnirile STOP Cancer „Inițiativa Stop Cancer (2)
01 – „Inițiativa STOP Cancer (1)”
01 – Întâlnirile STOP Cancer „Inițiativa Stop Cancer (1)
10 – Întâlnirile STOP Cancer „Consiliere psihologică/nutriţie (2)
9 Întâlnirile STOP Cancer „Consiliere psihologică/nutriţie”
9 Întâlnirile STOP Cancer „Consiliere psihologică/nutriţie”
08 Întâlnirile STOP Cancer „Cancerul mamar”
08 Întâlnirile STOP Cancer – „Cancerul mamar”
7 Întâlnirile STOP Cancer „Cancerul de col uterin”
07 Întâlnirile STOP Cancer „Cancerul de col uterin”
06 Întâlnirile STOP Cancer – Melanomul malign (2)
6 – Întâlnirile STOP Cancer „Melanomul malign (2)”
05 Întâlnirile STOP Cancer – „Cancerul brohmopulmonar”
5 – Întâlnirile STOP Cancer „Cancerul brohmopulmonar”
04 Întâlnirile STOP Cancer – „Melanomul malign”
04 Întâlnirile STOP Cancer – „Melanomul malign”
03 Întâlnirile STOP Cancer – „Covid vs Cance(2)?”
03 Întâlnirile STOP Cancer – „Covid vs Cance(2)?”
2 – Întâlnirile STOP Cancer „Covid-19 vs Cancer?
1 – Intalnirile STOP Cancer
Ce trebuie sa stii despre Radioterapie
It may comfort you to know that Fry’s death took only fifteen seconds, yet the pain was so intense, that it felt to him like fifteen years.
Continue readingMieloame
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2) | In curs de recrutate | Research Site, Bucharest, Romania, 022328Research Site, Bucharest, Romania, 030171Research Site, Bucharest, Romania, 050098Research Site, Bucuresti, Romania, 020125Research Site, Cluj-Napoca, Romania, 400124Research Site, Iasi, Romania, 700483Research Site, Oradea, Romania, 410469Research Site, Sibiu, Romania, 550245Research Site, Timisoara, Romania, 300079 |
| 2 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR) | Activ, inca nu se recruteaza | Research Site, Brasov, Romania, 500152Research Site, Bucharest, Romania, 030171Research Site, Bucharest, Romania, 050098Research Site, Bucuresti, Romania, 020125Research Site, Bucuresti, Romania, 022328Research Site, Cluj-Napoca, Romania, 400124Research Site, Craiova, Romania, 200143 |
| 3 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1) | Activ, inca nu se recruteaza | Local Institution, Brasov, Romania, 500152Local Institution, Bucuresti, Romania, 030171Local Institution, Bucuresti, Romania, 020125Local Institution, Bucuresti, Romania, 050098Local Institution, Bucuresti, Romania, 22328Local Institution, Iasi, Romania, 700483 |
| 4 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) | Activ, inca nu se recruteaza | Hyperclnical MedLife PDR Vulturului Brasov, Hematology Department, Braşov, Romania, 500366Colentina Clinical Hospital, Department of Hematology, Bucharest, Romania, 020125Bucharest University Emergency Hospital, Department of Hematology, Bucharest, Romania, 050098 |
| 5 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | Activ, inca nu se recruteaza | Brasov, RomaniaBucharest, RomaniaIasi, Romania |
| 6 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN) | Activ, inca nu recruteaza | RO-02, Braşov, RomaniaRO-01, Bucharest, Romania |
Mezotelioame
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab) | Activ, inca nu se recruteaza | Research Site, Craiova, Romania, 200385 |
| 2 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Activ, inca nu se recruteaza | Local Institution, Bucharest, Romania, 020122Local Institution, Bucuresti, Romania, 021389Local Institution, Craiova, Romania, 200347Local Institution, Romania, Romania, 400015 |
Limfoame
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4) | Activ, nu se recruteaza | Sp. Judetean de Urgenta Dr. Constantin Opris Baia Mare, Baia Mare, Romania, 430031S.C. Policlinica de Diagnostic Rapid S.A., Brasov, Romania, 500152Fundeni Clinical Institute, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucharest, Romania, 030171Sp. Univ. de Urgenta Militar Central Dr. Carol Davila, Bucuresti, Romania, 010825Spitalul Clinic Colentina, Bucuresti, Romania, 020125Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania, 200143Institutul Regional de Oncologie Iasi, Iasi, Romania, 700111Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Spitalul Clinic Judetean de Urgenta Targu-Mures, Targu-Mures, Romania, 540136 |
| 2 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3) | Activ, inca nu se recruteaza | Brasov, Romania, 500152Bucharest, Romania, 030171Bucuresti, Romania, 010825Bucuresti, Romania, 020125Bucuresti, Romania, 022328Cluj-Napoca, Romania, 400015Craiova, Romania, 200143Targu-Mures, Romania, 540136 |
| 3 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | Activ, inca nu se recruteaza | Institut Clinic Fundeni, Bucuresti, Romania, 22328Spitalul Clinic de Urgenta pentru Copii M.S. Curie, Bucuresti, Romania, 41451Institutul Oncologic ‘Prof Dr. Ion Chiricuta’ Cluj-Napoca , Cluj-Napoca, Romania, 400015Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea, Oradea, RomaniaSpitalul Clinic de Urgenta pentru Copii ‘Louis Turcanu’, Timisoara, Romania, 300011 |
| 4 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | In curs de recrutare | Spitalul Judetean de Urgenta Dr.Constantin Opris Baia Mare, Baia Mare, RomaniaSpitalul Clinic Coltea, Bucuresti, RomaniaInstitutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca, RomaniaInstitutul Regional De Oncologie IASI, Iasi, Romania |
| 5 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (ECHELON-2) | Activ, inca nu se recruteaza | Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucuresti, Romania, 030171Institutul Oncologic „Prof. Dr. I. Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular, Targu Mures, Romania, 540136 |
| 6 | Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | Activ, inca nu se recruteaza | Policlinica de Diagnostic Rapid SA, Brasov, Romania, 500152Spitalul Clinic Colentina, Bucuresti, Romania, 020125Spitalul Clinic Coltea, Bucuresti, Romania, 030171Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania, 540042 |
| 7 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) | In curs de recrutare | MorphoSys Research Site, Bucharest, Romania, 022328MorphoSys Research Site, Bucharest, Romania, 30171MorphoSys Research Site, Iaşi, Romania, 700483 |
| 8 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | In curs de recrutare | Cluj NapocaIon Chiricuta Oncology Institute, Cluj Napoca, Romania, 400015 Contact: Ciprian Tomuleasa, MD 0040741337480 ciprian.tomuleasa@umfcluj.ro Contact: Catalin Vlad, MD 0040264598362 catalinvlad@yahoo.it |
Leucemii
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) | Activ, inca nu se recruteaza | Institutul Regional de Oncologie Iași, Iași, Romania, 20125Spitalul Clinic Colentina, Bucuresti, Romania, 20125Spitalul Clinic Coltea, Bucuresti, Romania, 20125Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania, 20125Institutul Clinic Fundeni, Bucuresti, Romania, 22328Institutul Oncologic „Prof. Dr. Ion Chiricuţă” Cluj Napoca, Cluj-Napoca, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania, 200143Spitalul Clinic Judetean de Urgenta Târgu-Mureş (4005), Târgu-Mureş, Romania, 540042Spitalul Clinic Judetean de Urgenta Târgu-Mureş (4008), Târgu-Mureş, Romania, 540136 |
| 2 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019) | Activ, inca nu se recruteaza | Institutul Oncologic ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Cluj, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Sectia Clinica Hematologie, Craiova, Dolj, Romania, 200136Spitalul Universitar de Urgenta Militar Central „Dr. Carol Davila” Bucuresti, Bucuresti, Romania, 010825Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania, 030171 |
| 3 | Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia. | Acitv, inca nu se recruteaza | Novartis Investigative Site, Bucharest, District 2, Romania, 022328Novartis Investigative Site, Tg Mures, Mures, Romania, 540136Novartis Investigative Site, Craiova, Romania, 200136Novartis Investigative Site, Iasi, Romania, 700483 |
| 4 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | Activ, inca nu se recruteaza | Site RO40005, București, Romania |
| 5 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | Activ, inca nu se recruteaza | Novartis Investigative Site, Bucharest, District 2, Romania, 022328Novartis Investigative Site, Bucharest, Romania, 030171Novartis Investigative Site, Cluj-Napoca, Romania, 400124Novartis Investigative Site, Craiova, Romania, 200136Novartis Investigative Site, Timisoara, Romania, 300079 |
| 6 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL | Activ, inca nu se recruteaza | Research Site, Bucharest, Romania, 022328Research Site, Cluj-Napoca, Romania, 400177 |
| 7 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | In curs de recrutare | Insitutul Clinic Fundeni, Sectia de Transplant Medular, Bucharest, Romania, Contact: Anca Colita, MD PhD, ancacolita@yahoo.com Principal Investigator: Anca Colita, MD PhD University of Medicine and Pharmacy V. BABES, Emergency Children’s Hospital LOUIS TURCANU, III. Clinic of Pediatrics , Department of Onco-hematology and Bone Marrow Transplantation, Timişoara, Romania, Contact: Cristian Jinca, MD PhD, cristian_jinca@yahoo.com Principal Investigator: Cristian Jinca, MD PhD |
| 8 | A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy | Activ, inca nu se recruteaza | Institutul Clinic Fundeni, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucharest, Romania, 030171Spitalul Clinic Judetean de Urgenta Sf Spiridon Iasi , Iasi, Romania, 700111Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Spitalul Clinic Municipal de Urgenta Timisoara, Timisoara, Romania, 300079 |
| 9 | A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia | Activ, inca nu se recruteaza | Fundeni Clinical Inst. ; Hematology Dept., Bucharest, Romania, 022328Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania, 700483Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania, 540136 |
| 10 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib | Activ, inca nu se recruteaza | Local Institution, Bucharest, Romania, 022322 |
| 11 | Safety, Tolerability, Pharmacokinetics and Activity of K0706 | In curs de recrutare | Spitalul Clinic Colentina Recruiting Bucuresti, Romania, 020125 Spitalul Clinic Coltea Recruiting Bucuresti, Romania, 030171 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca Recruiting Cluj-Napoca, Romania, 400124 Spitalul Clinic Municipal Filantropia Craiova Recruiting Craiova, Romania, 200143 Spitalul Clinic Judetean de Urgenta Targu Mures Recruiting Târgu Mureș, Romania, 540136 |
| 12 | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL | In curs de recrutare | Spitalul Clinic Municipal de Urgenta Timisoara Recruiting Timisoara, Timis, Romania, 300021 Spitalul Clinic Colentina Recruiting Bucuresti, Romania, 020125 Spitalul Universitar de Urgenta Bucuresti Recruiting Bucuresti, Romania, 50098 Institutul Regional de Oncologie Iasi Recruiting Iasi, Romania, 700483 |
Hepatocarcinoame
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX) | In curs de recrutare | Local Institution, Brasov, Romania, 500091, Contact: Site 0060 Local Institution, Bucharest, Romania, 022328, Contact: Site 0078 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0232 Local Institution, Constanta, Romania, 900591, Contact: Site 0242 Local Institution, Craiova, Romania, 200347, Contact: Site 0074 S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Romania, 300166, Contact: Roxana-Ioana Scheusan, Site 0070 +40745146020 |
| 2 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL) | Activ, inca nu se recruteaza | Cluj-Napoca, Cluj, Romania, 400015Brasov, Romania, 500019 |
| 3 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) | In curs de recrutare | Local Institution, Craiova, Dolj, Romania, 200347, Contact: Site 0103 Local Institution, Bucharest, Romania, 22328, Contact: Site 0164 Local Institution, Cluj Napoca, Romania, 400015, Contact: Site 0165 Local Institution, Craiova, Romania, 200385, Contact: Site 0208 Local Institution, Timisoara, Romania, 300166, Contact: Site 0163 |
| 4 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Activ, inca nu se recruteaza | Spitalul Pelican Impex SRL- Sectia Oncologie Medicala, Bihor, RomaniaInstitutul Clinic Fundeni – Sectia Oncologie Medicala, Bucuresti, RomaniaClinica Bendis – Oncologie Medicala, Cluj, RomaniaCentrul de Oncologie ONCOLAB, Dolj, RomaniaInstitutul Regional de Oncologie Iasi – Sectia Oncologie Medicala, Iaşi, RomaniaSC DACMED SRL – Oncologie, Prahova, RomaniaSpitalului Clinic Judetean de Urgenta – Sectia Oncologie Medicala, Sibiu, RomaniaSpitalul Judetean de Urgenta „Sf. Ioan Cel Nou” – sectia Oncologie Medicala, Suceava, Romania |
| 5 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) | In curs de recrutare | Exelixis Clinical Site #204 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400015 Exelixis Clinical Site #211 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400015 Exelixis Clinical Site #202 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400641 Exelixis Clinical Site #206 Active, not recruiting Bucuresti, Romania, 022328 Exelixis Clinical Site #209 Active, not recruiting Iaşi, Romania, 700483 |
| 6 | Contrast Enhanced Ultrasound Guidance Biopsy for the Diagnosis of Liver Tumors (ConCLUDe) | In curs de recrutare | Regional Institute of Gastroenterology and Hepatology „Octavian Fodor” Recruiting Cluj-Napoca, Please Enter The State Or Province, Romania, 400126 Contact: Tudor Mocan +40 799 861946 Mocan.Tudor@umfcluj.ro Contact: Ioana Rusu ioana.russu@yahoo.com |
Glioblastoame
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Surgery for Recurrent Glioblastoma (RESURGE) | In curs de recrutare | Department of Neurosurgery, Spitalul Clinic De Urgență „Bagdasar-Arseni” , Bucharest, Romania, 041915, Contact: George Petrescu, MD |
Diverse
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy. | Activ, inca nu recruteaza | SC Oncolab SRL, Craiova, Dolj, Romania, 200385S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Timis, Romania, 300166SC ONCOCENTER Oncologie Clinica SRL, Timisoara, Timis, Romania, 300210Spitalul Clinic C.F. 2 Bucuresti. Departament Oncologie, Sectia Medicala 2, Bucuresti, Romania, 011464 |
| 2 | Pan Tumor Nivolumab Rollover Study | In curs de recrutare | Local Institution, Bucharest, Romania, 022328, Contact: Site 0129 Local Institution, Cluj Napoca, Romania, 400015, Contact: Site 0135 Local Institution, Cluj Napoca, Romania, 400641, Contact: Site 0127 Local Institution, Oradea, Romania, 440445, Contact: Site 0133 |
| 3 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) | In curs de recrutare | Local Institution, Bucuresti, Romania, 022328Local Institution, Cluj-Napoca, Romania, 400015Local Institution, Craiova, Romania, 200347Local Institution, Floresti, Romania, 407280Local Institution, Timisoara, Timis, Romania, 300239 |
| 4 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Activ, inca nu recruteaza | S.C Delta Health Care S.R.L, Bucuresti, Romania, 014142S.C Medisprof S.R.L., Cluj-Napoca, Romania, 400641S.C Centrul de Oncologie Sf. Nectarie S.R.L., Craiova, Romania, 200347S.C Oncocenter Oncologie Clinica S.R.L., Timişoara, Romania, 300166 |
| 5 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | In curs de recrutare | S.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102), Oradea, Bihor, Romania, 410469, Contact: Study Coordinator +40746103306 SC Radiotherapy Center Cluj SRL ( Site 1105), Comuna Floresti, Cluj, Romania, 407280, Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103), Craiova, Dolj, Romania, 200347, Contact: Study Coordinator +40727774974 Spitalul PDR Medlife ( Site 1106), Brasov, Romania, 500152, Contact: Study Coordinator +40722559551 S.C.Focus Lab Plus S.R.L ( Site 1101), Bucuresti, Romania, 021389, Contact: Study Coordinator +40721298677 S.C.Gral Medical S.R.L ( Site 1104), Bucuresti, Romania, 031422, Contact: Study Coordinator +40723954705 Medisprof ( Site 1107), Cluj Napoca, Romania, 400641, Contact: Study Coordinator +40751274636 |
| 6 | Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer | In curs de recrutare | Research Site, Bucharest, Romania, 022328Research Site, Cluj-Napoca, Romania, 400015Research Site, Cluj-Napoca, Romania, 400124Research Site, Timisoara, Romania, 300239 |
| 7 | An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | In curs de recrutare | Local Institution, Bucharest, Romania, 022328, Contact: Site 0045 Local Institution, Craiova, Romania, 200347, Contact: Site 0041 |
| 8 | A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | In curs de recrutare | Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania, 400015Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania, 400015ONCOMED – Medical Centre, Timisoara, Romania, 300239 |
| 9 | Durvalumab Long-Term Safety and Efficacy Study (WAVE) | In curs de recrutare | Research Site, Craiova, Romania, 200347Research Site, Suceava, Romania, 720237 |
| 10 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) | In curs de recrutare | Centrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347 |
| 11 | Avelumab Program Rollover Study | In curs de recrutare | Spitalul Clinic Municipal „Dr. Gavril Curteanu” Oradea – Centrul Oncologie Medicala, Oradea, Romania, 410469, Contact: simonamihutiu@yahoo.com, Principal Investigator: Simona Mihutiu |
| 12 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | Activ, inca nu recruteaza | Novartis Investigative, Bucuresti, Romania, 011863 |
| 13 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV) | Activ, inca nu se recruteaza | Emergency Clinical County Hospital Brasov, Brasov, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaColtea Clinical Hospital, Bucharest, Romania |
| 14 | A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS) | In curs de recrutare | Fundeni CLinical Institute, Clinic of Hematology, Bucharest, Romania |
| 15 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | Activ, inca nu se recruteaza | Institutul Oncologic Bucuresti Bucharest, Romania Spitalului Universitar de Urgenta Militar Central Bucharest, Romania Amethyst-Cluj Floresti, Romania County Hospital ‘Dr Gavril Curteanu’ Oradea, Romania County Hospital, Targu Mures Targu Mures, Romania Municipal Emergency Hospital Timisoara, Romania |
Cancerele urinare
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | Activ, inca nu se recruteaza | Oncomed SRL, Timisoara, JUD. Timis, Romania, 300239Institutul Oncologic „Prof.Dr.I.Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015 |
| 2 | An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer | In curs de recrutare | Bucharest, RomaniaCluj-Napoca, RomaniaCraiova, RomaniaIasi, Romania |
| 3 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | Activ, inca nu se recruteaza | „Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania, 400015S.C. Medisprof S.R.L., Cluj-Napoca, Romania, 400641″Sfantul Nectarie” Oncology Center, Craiova, Romania, 200347Oncomed SRL, Timisoara, Romania, 300239 |
| 4 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) | In curs de recrutare | Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0191 Local Institution, Craiova, Romania, 200347, Contact: Site 0187 |
| 5 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | Activ, inca nu se recruteaza | Oncopremium Team Srl, Baia Mare, Romania, 430291Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter, Cluj-Napoca, Romania, 400015Centrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347Centrul de Radioterapie AMETHYST, Floresti, Romania, 407280Oncomed SRL; Oncologie, Timisoara, Romania, 300239 |
| 6 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274) | Activ, inca nu se recruteaza | Local Institution, Bucuresti, Romania, 021389Local Institution, Craiova, Romania, 200347Local Institution, Floresti, Romania, 407280Local Institution, Timisoara, Timis, Romania, 300239 |
| 7 | A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC | In curs de recrutare | Institute Of Oncology „Prof.Dr.Alexandru Trestioreanu” Bucharest, Bucharest, Romania, 020122, Contact: Aurelia Alexandru, Site 0058 Local Institution, Craiova, Romania, 200347, Contact: Site 0076 |
| 8 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal) | In curs de recrutare | County Hospital Alba; Oncology, Alba Iulia, Romania, 510073Centrul Medical Focus; Oncologie medicala, Bucharest, Romania, 021389University Clinical Emergency Hospital Bucharest, Bucharest, RomaniaInstitutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania, 022328Sanador Medical Center; Medical Oncology, Bucuresti, RomaniaSpitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, Romania, 900591Institutul Regional de Oncologie Iasi, Iasi, Romania, 700483Spitalul Municipal Ploiesti, Ploiesti, Romania, 100337Oncomed SRL; Oncologie, Timisoara, Romania, 300239Oncocenter Timisoara , Timişoara, Romania, 300166 |
| 9 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE) | Activ, inca nu se recruteaza | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician. Baia Mare, Romania, 430110Cluj-Napoca, Romania, 400058Craiova, Romania, 200347 |
| 10 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914) | In curs de recrutare | Local Institution, Bucharest, Romania, 50659, Contact: Site 0201 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0200 Local Institution, Craiova, Romania, 200347, Contact: Site 0199 Local Institution, Lasi, Romania, 700483, Contact: Site 0202 |
| 11 | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Activ, inca nu se recruteaza | Local Institution, Bucharest, Romania, 014142, Contact: Site 0076 Local Institution, Bucharest, Romania, 020122, Contact: Site 0061 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0056 Local Institution, Constanta, Romania, 900591, Contact: Site 0059 Local Institution, Craiova, Romania, 200347, Contact: Site 0065 |
| 12 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130) | Activ, inca nu se recruteaza | Spitalul Judetean de Urgenta Dr Constantin Opris, Baia Mare, Romania, 430031Institute Of Oncology Bucharest; Medical Oncology, Bucharest, Romania, 022338Oncology Center Sf. Nectarie, Craiova, Romania, 200347 |
| 13 | Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma | Activ, inca nu se recruteaza | Medisprof SRL, Cluj-Napoca, RomaniaProf Dr I Chiricuta Institute of Oncology, Cluj-Napoca, RomaniaOncology Center Sfantul Nectarie, Craiova, RomaniaOncocenter Clinical Oncology, Timisoara, Romania |
| 14 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) | Activ, inca nu se recruteaza | Instit. Prof.Dr.Ion Chiricuta, Cluj-Napoca, Romania, 400015Sf. Nectarie Oncology Center, Craiova, Romania, 200347 |
| 15 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | In curs de recrutare | Centrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania, 200347Oncolab SRL, Craiova, Dolj, Romania, 200385Medisprof SRL , Cluj-Napoca, Romania, 400461Clinical Emergency Hospital of Constanta, Constanta, Romania, 900591Center of Oncology Euroclinic, Iasi, Romania, 700106Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Oncocenter – Oncologie Clinica SRL, Timisoara, Romania, 300166 |
| 16 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | In curs de recrutare | Spitalul Clinic Judetean de Urgenta ‘Sf Apostol Andrei’ Constanta Not yet recruiting Constanta, Romania, 900591 |
| 17 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Activ, nu se recruteaza | Local Institution Bucharest, Romania, 020122 Local Institution Cluj-Napoca, Romania, 400015 Local Institution Constanta, Romania, 900591 Local Institution Craiova, Romania, 200347 |
| 18 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | Activ, nu se recruteaza | Local Institution Bucharest, Romania, 022328 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167 |
| 19 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) | In curs de recrutare | Local Institution Not yet recruiting Bucharest, Romania, 022328 Contact: Site 0039 Local Institution Not yet recruiting Cluj-Napoca, Romania, 400015 Contact: Site 0014 Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0013 |
| 20 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | In curs de recrutare | S.C. Radiotherapy Center Cluj S.R.L ( Site 0252) Recruiting Cluj-Napoca, Cluj, Romania, 407280 Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248) Recruiting Craiova, Dolj, Romania, 200347 Contact: Study Coordinator +40722161545 |
Cancerele pielii
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | In curs de recrutare | Local Institution, Bucharest, Romania, 022328, Contact: Site 0066 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0070 Local Institution, Craiova, Romania, 200347, Contact: Site 0067 Local Institution, Lasi, Romania, 700483, Contact: Site 0069 |
| 2 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | In curs de recrutare | Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0070 Local Institution, Craiova, Romania, 200347, Contact: Site 0071 Local Institution, Floresti, Romania, 407280, Contact: Site 0120 Local Institution, Oradea, Romania, 410469, Contact: Site 0073 |
| 3 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) | In curs de recrutare | Local Institution, Bucharest, Romania, 020122, Contact: Site 0021 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0047 Local Institution, Craiova, Romania, 200347, Contact: Site 0020 |
| 4 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Activ, inca nu se recruteaza | Institute Of Oncology „Prof.Dr.Alexandru Trestioreanu” Bucharest, Bucharest, Romania, 022328Sf. Nectarie Oncology Center, Craiova, Romania, 200347 |
| 5 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) | Activ, inca nu se recruteaza | Local Institution, Craiova, Romania, 200347Local Institution, Romania, Romania, 400015 |
| 6 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | In curs de recrutare | Nova Clin Medical Research Center, Timisoara, Romania, 300696, Contact: Alexandru Bolocan, Site 0030 |
| 7 | Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | In curs de recrutare | Spitalul Universitar CF Cluj-Napoca ( Site 1103) RecruitingCluj-Napoca, Cluj, Romania, 400015, Contact: Study Coordinator +40724283983 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1101), Craiova, Dolj, Romania, 200347, Contact: Study Coordinator +40727774974 S C Oncocenter Oncologie Medicala S R L (Site 1106), Timisoara, Timis, Romania, 300166, Contact: Study Coordinator +40745146020 Hifu Terramed Conformal SRL ( Site 1111), Bucharest, Romania, 031864, Contact: Study Coordinator +40723599588 S.C.Focus Lab Plus S.R.L ( Site 1107), Bucuresti, Romania, 021389, Contact: Study Coordinator +40721298677 Cardiomed SRL Cluj-Napoca ( Site 1104), Cluj-Napoca, Romania, 400015, Contact: Study Coordinator +40724543672 S C Pelican Impex SRL ( Site 1108), Oradea, Romania, 410450, Contact: Study Coordinator +40746103306 Policlinica Oncomed SRL ( Site 1105), Timisoara, Romania, 300239, Contact: Study Coordinator +40744571617 |
| 8 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Activ, inca nu se recruteaza | Centrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania, 200347Oncolab SRL, Craiova, Dolj, Romania, 200385Medisprof SRL , Cluj-Napoca, Romania, 400461Clinical Emergency Hospital of Constanta, Constanta, Romania, 900591Center of Oncology Euroclinic, Iasi, Romania, 700106Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Oncocenter – Oncologie Clinica SRL, Timisoara, Romania, 300166 |
Cancere tiroidiene
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) | In curs de recrutare | Bucharest, Romania, 10825, Contact: Contact 1-888-EXELIXIS (888-393-5494) Bucharest, Romania, 11863, Contact: Contact 1-888-EXELIXIS (888-393-5494) Cluj-Napoca, Romania, 400058, Contact: Contact 1-888-EXELIXIS (888-393-5494) Cluj-Napoca, RomaniaTimisoara, Romania, 300723 |
| 2 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy | In curs de recrutare | Exelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania, 400015Exelixis Clinical Site #150, Craiova, Dolj, Romania, 200385Exelixis Clinical Site #142, Timişoara, Timis, Romania, 300166Exelixis Clinical Site #146, Bucuresti, Romania, 011863 |
| 3 | A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Activ, inca nu se recruteaza | Facility #1, Cluj-Napoca, Cluj, Romania, 400058Facility #1, Bucharest, Romania, 11863 |
| 4 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | Activ, inca nu se recruteaza | Investigational Site Number 1801, Bucharest, Romania |
Cancere pulmonare
| Nr. Crt. | Nume | Status | Locatie |
| 1 | Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) | Activ, inca nu recruteaza | SpitalulJudetean de Urgenta „Dr. Constantin Opris” Baia Mare Baia Mare, Romania, 430031 S.C Policlinica de Diagnostic Rapid S.A Brasov, Romania, 500152 Institutul Oncologic „Prof. Dr. Al. Trestioreanu” Bucuresti, Romania, 022328 Spitalul Clinic Coltea Bucuresti, Romania, 030171 S.C Gral Medical S.R.L Bucuresti, Romania, 031422 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj Napoca Cluj Napoca, Romania, 400015 S.C Medisprof S.R.L Cluj-Napoca, Romania, 400058 SpitalulMilitar de Urgenta „Dr.ConstantinPapilian”Cluj -Napoca Cluj-Napoca, Romania, 400132 S.C Radiotherapy Center Cluj S.R.L ComunaFloresti, Romania, 407280 Spitalul Clinic Judetean de Urgenta „Sf. Apostol Andrei” Constanta Constanta, Romania, 900591 S.C Centrul de Oncologie Sf. Nectarie S.R.L Craiova, Romania, 200347 Institutul Regional de Oncologie Iasi Iasi, Romania, 700483 S.C Pelican Impex S.R.L Oradea, Romania, 410469 Spitalul Clinic Municipal „Dr. Gavril Curteanu” Oradea Oradea, Romania, 410469 SpitalulJudetean de Urgenta „Sf. IoancelNou” Suceava Suceava, Romania, 720201 S.C OncocenterOncologieClinica S.R.L Timisoara, Romania, 300210 S.C Oncomed S.R.L Timisoara, Romania, 300239 |
| 2 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 010991 Local Institution Bucharest, Romania, 020122 Local Institution Craiova, Romania, 200347 Local Institution Lasi, Romania, 700106 Local Institution Romania, Romania, 400015 Local Institution Timisoara, Timis, Romania, 300239 |
| 3 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | Activ, inca nu recruteaza | ImClone Investigational Site Brasov, Romania, 500366 ImClone Investigational Site Bucharest, Romania, 022328 ImClone Investigational Site Bucharest, Romania, 030171 ImClone Investigational Site Cluj-Napoca, Romania, 400015 ImClone Investigational Site Craiova, Dolj, Romania, 200385 ImClone Investigational Site Iasi, Romania, 700106 ImClone Investigational Site Piatra Neamt, Romania, 610136 ImClone Investigational Site Sibiu, Romania, 550245 |
| 4 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | In curs de recrutare | S.C Gral Medical S.R.L Bucuresti, Romania Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania S.C Medisprof S.R.L Cluj-Napoca, Romania S.C Centrul de Oncologie Sf. Nectarie Craiova, Romania S.C Radiotherapy Center Cluj S.R.L Floreşti, Romania S.C OncocenterOncologieClinica S.R.L Timisoara, Romania Oncomed SRL Timişoara, Romania |
| 5 | First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin | Activ, inca nu recruteaza | ImClone Investigational Site Brasov, Romania, 500366 ImClone Investigational Site Bucharest, Romania, 022328 ImClone Investigational Site Bucharest, Romania, 030171 ImClone Investigational Site Cluj-Napoca, Romania, 400015 ImClone Investigational Site Craiova, Dolj, Romania, 200385 ImClone Investigational Site Iasi, Romania, 700106 ImClone Investigational Site Sibiu, Romania, 550245 |
| 6 | Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A | In curs de recrutare | Novartis Investigative Site Floresti, Cluj, Romania, 407280 Novartis Investigative Site Bucharest, Romania, 022328 Novartis Investigative Site Bucuresti, Romania, 010991 Novartis Investigative Site Cluj-Napoca, Romania, 400124 Novartis Investigative Site Craiova, Romania, 200347 Novartis Investigative Site Iasi, Romania, 700483 Novartis Investigative Site Timisoara, Romania, 300239 |
| 7 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | In curs de recrutare | Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoc ( Site 0501) Cluj Napoca, Cluj, Romania, 400015 Contact: Study Coordinator +40745976913 SC Radiotherapy Center Cluj SRL ( Site 0509) ComunaFloresti, Cluj, Romania, 407280 Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0504) Craiova, Dolj, Romania, 200347 S.C.R.T.C.Radiology Therapeutic Center SRL ( Site 0511) Otopeni, Ilfov, Romania, 075100 Contact: Study Coordinator +40723171603 S.C.Focus Lab Plus S.R.L ( Site 0513) Bucuresti, Sector 2, Romania, 021389 Contact: Study Coordinator +40721298677 S C OncocenterOncologieMedicala S R L ( Site 0505) Timisoara, Timis, Romania, 300166 Contact: Study Coordinator +40745146020 Spitalul Sf. Constantin ( Site 0512) Brasov, Romania, 500091 Contact: Study Coordinator +40724630750 Euroclinic Hospital Bucharest ( Site 0510) Bucuresti, Romania, 014461 Contact: Study Coordinator +40744848887 Affidea Romania SRL ( Site 0514) Bucuresti, Romania, 022328 Contact: Study Coordinator +40743424144 Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoc ( Site 0515) Cluj-Napoca, Romania, 400015 Contact: Study Coordinator +40745646368 Spitalul clinic Judetean de urgenta Constanta ( Site 0508) Constanta, Romania, 900591 Contact: Study Coordinator +40724877013 S C Pelican Impex SRL ( Site 0506) Oradea, Romania, 410450 Contact: Study Coordinator +40746103306 SpitalulJudetean de Urgenta .Sf. IoancelNou. ( Site 0503) Suceava, Romania, 720237 Contact: Study Coordinator +40722423653 |
| 8 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | In curs de recrutare | Centrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347 Contact 40351401336 Principal Investigator: Michael Schenker Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 Contact 40723289606 Principal Investigator: Aurelia Alexandru SC Gral Medical SRL Bucuresti, Romania, 031422 Contact 40213230000 Principal Investigator: Cristina Tiut SpitalulUniversitar de UrgentaBucuresti Bucuresti, Romania, 050098 Contact 4072145891 Principal Investigator: PolixeniaGeorgetaIorga Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania, 400015 Contact 40745646368 Principal Investigator: Tudor Ciuleanu Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta, Romania, 900591 Contact 40241662222 Principal Investigator: Laura Mazilu SpitalulJudetean de Urgenta „Sf. IoancelNou” Suceava, Romania, 720237 Contact 40230515554 Principal Investigator: Doina Elena Ganea-Motan Oncomed SRL Timisoara, Romania, 300239 Contact 40256495403 Principal Investigator: Cristina Oprean |
| 9 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 022328 Local Institution Bucharest, Romania, 030171 Local Institution Cluj Napoca, Romania, 400058 Local Institution Cluj-Napoca, Romania, 400015 Local Institution Oradea, Romania, 410469 Local Institution Timisoara, Romania, 300167 |
| 10 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | Activ, inca nu recruteaza | Research Site Alba Iulia, Romania, 510077 Research Site Baia Mare, Romania, 430031 Research Site Cluj Napoca, Romania, 400349 Research Site Cluj-Napoca, Romania, 400132 Research Site Onesti, Romania, 601048 Research Site Oradea, Romania, 410469 Research Site Timisoara, Romania, 300210 |
| 11 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | Activ, inca nu recruteaza | Local Institution Bucuresti, Romania, 010976 Local Institution Cluj-Napoca, Romania, 400352 Local Institution Constanta, Romania, 900591 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167 |
| 12 | A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] | Activ, inca nu recruteaza | Teo Health SA – Saint Constantin Hospital Brasov, Romania, 500091 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 Institutul Regional de Oncologie Iasi; Clinica de Hematologie Iasi, Romania, 700483 Sibiu Emergency Clinical County Hospital Sibiu, Romania, 550245 Oncomed SRL Timisoara, Romania, 300239 Oncocenter Clinical Oncology Timişoara, Romania, 300210 |
| 13 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer | Activ, inca nu recruteaza | Focus Lab Plus SRL Bucuresti, Romania, 021389 Sf. Nectarie Oncology Center Craiova, Romania, 200347 Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep Romania, Romania, 400015 |
| 14 | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Activ, inca nu recruteaza | Research Site Bucharest, Romania, 050098 Research Site Bucuresti, Romania, 022328 Research Site Craiova, Romania, 200347 |
| 15 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | In curs de recrutare | Institute Of Oncology „Prof.Dr.AlexandruTrestioreanu” Bucha Bucharest, Romania, 022328 Sf. Nectarie Oncology Center Craiova, Romania, 200347 S.C. Radiotherapy Center Cluj S.R.L. Floresti, Romania, 407280 Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep Romania, Romania, 400015 |
| 16 | A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy | Activ, inca nu recruteaza | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; OncologieMedicala Completed Cluj Napoca, Romania, 400015 Centrul de Radioterapie AMETHYST Completed Floresti, Romania, 407280 Oncocenter Timisoara Completed Timişoara, Romania, 300166 |
| 17 | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | Activ, inca nu recruteaza | Medisprof SRL Cluj-Napoca, Romania, 400058 Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta Constanta, Romania, 900591 Euroclinic Center of Oncology SRL Iasi, Romania, 700106 |
| 18 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Activ, inca nu recruteaza | Local Institution Cluj Napoca, Romania, 400015 Local Institution Cluj-napoca, Romania, 400352 Local Institution Ploiesti, Romania, 100337 |
| 19 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) | Activ, inca nu recruteaza | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician. Baia Mare, Romania, 430031 Bucharest, Romania, 022328 Cluj-Napoca, Romania, 400015 Cluj-Napoca, Romania, 400058 Craiova, Romania, 200347 |
| 20 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | Activ, inca nu recruteaza | Conformal Med Terra HIFU Bucharest, Romania, 031864 Spitalul de Psihiatrie Dr. Constantin Gorgos Bucharest, Romania, 30447 Oncology Institute Bucharest Bucharest, Romania Oncological Institute „Ion Chiricuta” Cluj-Napoca, Romania, 3400 OCH – Ovidius Clinical Hospital Constanta, Romania, 905900 Centrul de Oncologie Sf Nectarie Craiova, Romania, 200347 SC Oncolab SRL Craiova, Romania, 200385 Spital Lotus SRL Ploiesti, Romania, 100011 |
| 21 | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | In curs de recrutare | Local Institution Bucharest, Romania, 022328 Contact: Site 0018 Local Institution Cluj-Napoca, Romania, 400015 Contact: Site 0019 Local Institution Constanta, Romania, 900591 Contact: Site 0020 Local Institution Craiova, Romania, 200347 Contact: Site 0017 Local Institution Floresti, Romania, 407280 Contact: Site 0021 |
| 22 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | Activ, inca nu recruteaza | Local Institution Bucuresti, Romania, 010976 Local Institution Cluj-Napoca, Romania, 400352 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167 |
| 23 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Activ, inca nu recruteaza | Clinical Study Site 1 Craiova, Romania Clinical Study Site 2 Craiova, Romania Clinical Study Site Floreşti, Romania Clinical Study Site Ploieşti, Romania Clinical Study Site Timişoara, Romania |
| 24 | Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer | In curs de recrutare | Institutul Oncologic /ID# 206320 Cluj Napoca, Romania, 400015 Oncomed SRL /ID# 205616 Timisoara, Romania, 300239 |
| 25 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | Activ, inca nu recruteaza | Institute Of Oncology „Prof.Dr.AlexandruTrestioreanu” Bucha Bucharest, Romania, 020122 Sf. Nectarie Oncology Center Craiova, Romania, 200347 Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep Romania, Romania, 400015 |
| 26 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 020122 Local Institution Craiova, Romania, 200347 |
| 27 | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | Activ, inca nu recruteaza | Institutul Oncologic „Prof. Dr. Ion Chiricuţă” Cluj Napoca Recruiting Cluj-Napoca, Romania, 400015 Contact: Dr Tudor-Eliade Ciuleanu Medisprof SRL Recruiting Cluj-Napoca, Romania, 400641 Contact: Dr. Anghel Adrian Udrea Centrul de Oncologie, S.C. Centrul de Oncologie Sf. Nectarie S.R.L, Recruiting Craiova, Romania, 200347 Contact: Dr Michael Schenker Oncocenter – OncologieClinica SRL Recruiting Timişoara, Romania, 300166 Contact: Dr Roxana Scheusan |
| 28 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | In curs de recrutare | Prof Dr I Chiricuta Institute of Oncology Cluj-Napoca, Romania, 400015 Sf. Nectarie Oncology Center Craiova, Romania, 200347 |
| 29 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | Activ, inca nu recruteaza | Local Institution Active, not recruiting Bucharest, Romania, 020122 Local Institution Active, not recruiting Cluj-Napoca, Romania, 400015 Local Institution Active, not recruiting Craiova, Romania, 200347 |
| 30 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | In curs de recrutare | Spitalul PDR Medlife ( Site 2509) Brasov, Romania, 500152 Contact: Study Coordinator +40722559551 S.C.Focus Lab Plus S.R.L ( Site 2502) Bucuresti, Romania, 021389 Contact: Study Coordinator +40721298677 Cardiomed SRL Cluj-Napoca ( Site 2504) Cluj Napoca, Romania, 400015 Contact: Study Coordinator +40724543672 S.C. Radiotherapy Center Cluj S.R.L ( Site 2507) Cluj-Napoca, Romania, 407280 Contact: Study Coordinator +40742206212 Spitalul Clinic Judetean De Urgenta Constanta ( Site 2501) Constanta, Romania, 900591 Contact: Study Coordinator +40724877013 PoliclinicaOncomed SRL ( Site 2505) Timisoara, Romania, 300239 Contact: Study Coordinator +40724543672 |
| 31 | Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC) | In curs de recrutare | GSK Investigational Site Bucharest, Romania, 020142 GSK Investigational Site Cluj-Napoca, Romania, 400641 GSK Investigational Site Craiova, Romania, 200347 GSK Investigational Site Floresti, Romania, 407280 GSK Investigational Site Otopeni, Romania, 075100 GSK Investigational Site Timisoara, Romania, 300166 |
| 32 | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC | Activ, inca nu recruteaza | Research Site Cluj Napoca, Romania, 400015 Research Site Cluj Napoca, Romania, 400058 |
| 33 | AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. | Activ, inca nu recruteaza | Research Site Bucharest, Romania, 050098 Research Site Bucuresti, Romania, 031422 Research Site Cluj Napoca, Romania, 400015 Research Site Craiova, Romania, 200385 Research Site Focsani, Romania, 620165 Research Site Iasi, Romania, 700483 Research Site Timisoara, Romania, 300210 |
| 24 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | Activ, inca nu recruteaza | Novartis Investigative Site Cluj-Napoca, Romania, 400124 Novartis Investigative Site Craiova, Romania, 200347 |
| 35 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | Activ, inca nu recruteaza | Research Site Cluj Napoca, Romania, 400015 Research Site Floresti, Romania, 407280 Research Site Suceava, Romania, 720237 |
| 36 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Activ, inca nu recruteaza | Centrul de OncologieSfantulNectarie Craiova, Dolj, Romania, 200347 Oncolab SRL Craiova, Dolj, Romania, 200385 Medisprof SRL Cluj-Napoca, Romania, 400461 Clinical Emergency Hospital of Constanta Constanta, Romania, 900591 Center of Oncology Euroclinic Iasi, Romania, 700106 Spitalul Clinic Judetean de Urgenta Sibiu Sibiu, Romania, 550245 Oncocenter – OncologieClinica SRL Timisoara, Romania, 300166 |
| 37 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) | Activ, inca nu recruteaza | S.C. MedisProf SRL Cluj-Napoca, Cluj, Romania, 400058 Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 |
| 38 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | In curs de recrutare | S.C.Focus Lab Plus S.R.L ( Site 2502) Bucuresti, Romania, 021389 Contact: Study Coordinator +40721298677 Cardiomed SRL Cluj-Napoca ( Site 2504) Cluj Napoca, Romania, 400015 Contact: Study Coordinator +40728209986 S.C. Radiotherapy Center Cluj S.R.L ( Site 2507) Cluj-Napoca, Romania, 407280 Contact: Study Coordinator +40372693518 Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei ( Site 2501) Constanta, Romania, 900591 Contact: Study Coordinator +40724877013 PoliclinicaOncomed SRL ( Site 2505) Timisoara, Romania, 300239 Contact: Study Coordinator +40744571617 |
| 39 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal) | In curs de recrutare | County Hospital Alba; Oncology Alba Iulia, Romania, 510073 Centrul Medical Focus; Oncologiemedicala Bucharest, Romania, 021389 University Clinical Emergency Hospital Bucharest Bucharest, Romania Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Sanador Medical Center; Medical Oncology Bucuresti, Romania Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta Constanta, Romania, 900591 Institutul Regional de Oncologie Iasi Iasi, Romania, 700483 Spitalul Municipal Ploiesti Ploiesti, Romania, 100337 Oncomed SRL; Oncologie Timisoara, Romania, 300239 Oncocenter Timisoara Timişoara, Romania, 300166 |
| 40 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | In curs de recrutare | Local Institution Bucharest, Romania, 724351 Contact: Site 0011 Local Institution Cluj-Napoca, Romania, 400015 Contact: Site 0013 Local Institution Floresti, Romania, 407280 Contact: Site 0012 |
| 41 | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | Activ, inca nu recruteaza | Oncology Center Sf. Nectarie Craiova, Romania, 200347 |
| 42 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | Activ, inca nu recruteaza | Research Site 6105 Cluj-Napoca, Cluj, Romania, 400058 Research Site 6106 Cluj-Napoca, Cluj, Romania, 400352 Research Site 6108 Floreşti, Cluj, Romania, 407280 Research Site 6101 Baia Mare, Romania, 430031 Research Site 6102 Constanta, Romania, 900591 Research Site 6103 Craiova, Romania, 200385 Research Site 6107 Iasi, Romania, 700106 |
| 43 | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). | Activ, inca nu recruteaza | Research Site Suceava, Romania, 720237 |
| 44 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331) | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 020122 Local Institution Craiova, Romania, 200347 Local Institution Romania, Romania, 400015 Local Institution Timisoara, Timis, Romania, 300239 |
| 45 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | In curs de recrutare | Institutul Oncologic Prof. Dr. Alexandru Trestioreanu; Oncologie Medicala II Withdrawn Bucuresti, Romania, 022328 Cardiomed Medical Center Recruiting Cluj-Napoca, Romania, 400015 Prof Dr I Chiricuta Institute of Oncology; Oncology Department Not yet recruiting Cluj-napoca, Romania, 400015 Oncomed SRL; Oncologie Not yet recruiting Timisoara, Romania, 300239 Municipal Clinical Emergency Hospital Timisoara; Medical Oncology Clinic Not yet recruiting Timişoara, Romania, 300595 |
| 46 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | In curs de recrutare | Research Site Recruiting Bucharest, Romania, 022328 Research Site Recruiting Bucharest, Romania, 022338 Research Site Recruiting Bucharest, Romania, 030171 Research Site Recruiting Cluj Napoca, Romania, 400015 Research Site Recruiting Iasi, Romania, 700483 Research Site Recruiting Ploiesti, Romania, 100337 Research Site Recruiting Timisoara, Romania, 300239 |
| 47 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | In curs de recrutare | „Prof. Dr. Ion Chiricuta” Institute of Oncology, Medical Oncology Department Recruiting Cluj-Napoca, Cluj County, Romania, 400015 „Sf. Nectarie” Oncology center, Medical Oncology department Recruiting Craiova, Dolj County, Romania, 200347 SC Oncopremium team SRL, Medical oncology department Recruiting Baia Mare, Maramures, Romania, 430291 Topmed Medical center, Medical Oncology Department Recruiting Târgu-Mureş, Murers, Romania, 540156 Sf. Ioan cel Nou Country Emergency Hospital, Oncology department Recruiting Suceava, Suceava County, Romania, 720237 S.C. Oncomed SRL, Medical Oncology Department Recruiting Timisoara, Timis, Romania, 300239 Alexandru Trestioreanu Institute of Oncology Recruiting Bucharest, Romania, 022328 |
| 48 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Activ, inca nu recruteaza | Regeneron Research Site Bucuresti, Romania, 031422 Regeneron Research Site Cluj Napoca, Romania, 400124 Regeneron Research Site Craiova, Romania, 200094 Regeneron Research Site Craiova, Romania, 200347 Regeneron Research Site Craiova, Romania, 200385 Regeneron Research Site Iasi, Romania, 700106 Regeneron Research Site Iasi, Romania, 700483 Regeneron Research Site Timisoara, Romania, 300166 |
| 49 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) | In curs de recrutare | Research Site Not yet recruiting Constanta, Romania, 900591 Research Site Not yet recruiting Floresti, Romania, 407280 Research Site Not yet recruiting Suceava, Romania, 720237 |
| 50 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Activ, inca nu recruteaza | Local Institution Craiova, Romania, 200094 Contact: Site 0012 Local Institution Craiova, Romania, 200347 Contact: Site 0052 Local Institution Craiova, Romania, 200385 Contact: Site 0017 Local Institution Timisoara, Romania, 300166 Contact: Site 0069 |
| 51 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) | In curs de recrutare | Investigational Site Number 6420002 Recruiting Bucuresti, Romania, 10991 Investigational Site Number 6420006 Recruiting Craiova, Romania, 200347 Investigational Site Number 6420005 Recruiting Timisoara, Romania, 300166 Investigational Site Number 6420004 Recruiting Timisoara, Romania, 300239 |
| 52 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Activ, inca nu recruteaza | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala Cluj Napoca, Romania, 400015 Centrul de Radioterapie AMETHYST Floresti, Romania, 407280 Oncocenter Timisoara Timişoara, Romania, 300166 |
| 53 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (CheckMate 79X) | In curs de recrutare | Local Institution Craiova, Romania, 200347 Contact: Site 0025 Local Institution Timisoara, Romania, 300696 Contact: Site 0018 |
| 54 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) | In curs de recrutare | S C Oncocenter Oncologie Medicala S R L Recruiting Timisoara, Romania, 300166 |
| 55 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | In curs de recrutare | Research Site Not yet recruiting Suceava, Romania, 720237 |
| 56 | An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3) | In curs de recrutare | Institutul Oncologic Prof. Dr. Ion Chiricu Recruiting Cluj-Napoca, Cluj, Romania, 400015 Oncocenter- Oncologie Clinic Recruiting Timişoara, Timis, Romania, 300166 Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucaresti Recruiting Bucuresti, Romania, 022328 Centrul de oncologie Euroclinic Recruiting Iasi, Romania, 700106 |
| 57 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC (DOMAJOR) | In curs de recrutare | S.C Medisprof S.R.L Recruiting Cluj-Napoca, Romania Contact: Udrea A Anghel, MD S.C Radiotherapy Center Cluj S.R.L Recruiting Cluj, Romania Contact: Manolescu A Alexandru, MD „Sfantul Nectarie” Oncology Center SRL Recruiting Craiova, Romania Contact: Schenker Michael, MD S.C Oncolab S.R.L Recruiting Craiova, Romania Contact: Lungulescu Stefan, MD S.C Pelican Impex S.R.L Recruiting Oradea, Romania Contact: Puscas I Adriana, MD Emergency Clinical Municipal Hospital Timisoara – Medical Oncology Clinic Recruiting Timisoara, Romania Contact: Curescu Petra, MD S.C Oncocenter Clinical Oncology S.R.L Recruiting Timisoara, Romania Contact: Scheusan R Ioana, MD S.C Oncomed S.R.L Recruiting Timisoara, Romania Contact: Segarceanu N Alina, MD S.C Salvosan Ciobanca S.R. Recruiting Zalau, Romania Contact: Papp Margareta, MD |
Cancere pancreatice
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment | In curs de recrutare | Institutului Oncologic „Prof. Dr. Ion Chiricuţă”, Cluj-Napoca, Romania, Principal Investigator: Tudor Eliade Ciuleanu, MD Medisprof SRL, Cluj, Romania, Principal Investigator: Adrian Udrea, MD Oncolab, Craiova, Romania, Principal Investigator: Dan Stelian Lungulescu, MD Sf Nectarie Oncology Center, Craiova, Romania, Principal Investigator: Michael Schenker, MD Centrul de Oncologie Euroclinic, Iasi, Romania, Principal Investigator: Constantin Volovat, MD Oncohelp, Timisoara, Romania, Principal Investigator: Serban Negru, MD |
| 2 | Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer (PAC-MAIN) | In curs de recrutare | Clinical Emergency Hospital Bucharest Recruiting Bucharest, Romania Contact: Vasile Sandru, MD +0040728813095 drsandruvasile@gmail.com |
| 3 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | In curs de recrutare | Research Site Recruiting Bucharest, Romania, 022328 Research Site Recruiting Cluj-Napoca, Romania, 400015 Research Site Recruiting Cluj-Napoca, Romania, 400124 Research Site Recruiting Craiova, Romania, 200347 Research Site Recruiting Iasi, Romania, 700483 Research Site Recruiting Timisoara, Romania, 300239 |
Cancere ovariene
| Nr. Crt. | Nume | Status | Locatie |
| 1. | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. | In curs de recrutare | Research Site Not yet recruiting Bucuresti, Romania, 011171 Research Site Not yet recruiting Cluj Napoca, Romania, 400015 Research Site Withdrawn Cluj Napoca, Romania, 400058 Research Site Not yet recruiting Constanta, Romania, 900591 Research Site Not yet recruiting Floresti, Romania, 407280 Research Site Not yet recruiting Suceava, Romania, 720237 Research Site Not yet recruiting Timisoara, Romania, 300239 |
| 2. | A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer | In curs de recrutare | Medisprof SRL Recruiting Cluj-Napoca, Cluj, Romania, 400051 Centrul de Oncologie Sf. Nectarie Recruiting Craiova, Dolj, Romania, 200347 Institutul Oncologic A Trestioreanu Recruiting Bucuresti, Romania, 022328 Institutul Oncologic Prof Chiricuta Recruiting Cluj-Napoca, Romania, 400015 Spitalul Clinic JudeteanUrgenta Sf. Apostol Andrei Recruiting Constanţa, Romania, 900591 SC Oncomed SRL Recruiting Timisoara, Romania, 300239 |
| 3. | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | Activ, inca nu recruteaza | Research Site Baia Mare, Romania, 430222 Research Site Cluj-Napoca, Romania, 400015 Research Site Iasi, Romania, 700106 Research Site Suceava, Romania, 720237 |
| 4. | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | Activ, inca nu recruteaza | Institutul Oncologic „Prof. Dr. Ion Chiricuta” Recruiting Cluj-Napoca, Cluj, Romania, 400015 Spitalul Clinic Municipal „Dr. Gavril Curteanu” Recruiting Oradea, Jud. Bihor, Romania, 410469 S.C. Medisprof S.R.L. Recruiting Cluj-Napoca, Jud. Cluj, Romania, 400641 Teo Health SA – Spitalul Sf-Constantin Recruiting Braşov, Romania, 500091 Institutul Oncologic, Prof. Dr. AlexandruTrestioreanu Recruiting Bucharest, Romania, 022328 Centrul de OncologieSf.Nectarie Recruiting Craiova, Romania, 200347 Institutul Regional de Oncologie Iasi Recruiting Iaşi, Romania, 700489 SpitalulJudetean de Urgenta „SfantulIoancelNou” Suceava Recruiting Suceava, Romania, 720237 ONCOMED Timisoara Recruiting Timişoara, Romania, 300239 |
| 5. | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | In curs de recrutare | Research Site Recruiting Bucharest, Romania, 022328 Research Site Recruiting Bucharest, Romania, 022338 Research Site Recruiting Bucharest, Romania, 030171 Research Site Recruiting Cluj Napoca, Romania, 400015 Research Site Recruiting Iasi, Romania, 700483 Research Site Recruiting Ploiesti, Romania, 100337 Research Site Recruiting Timisoara, Romania, 300239 |
Cancere gastrice-jonctiune eso-gastrica
| Numele studiului | Status | Locatia/Locatiile studiului | |
| 1 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Activ, inca nu se recruteaza | Local Institution, Baia Mare, JUD Maramures, Romania, 430291Local Institution, Bucharest, Romania, 022328Local Institution, Cluj-Napoca, Romania, 400015Local Institution, Craiova, Romania, 200347Local Institution, Suceava, Romania, 720237 |
| 2 | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) | In curs de recrutare | Institutul Clinic Fundeni – Clinica Pediatrie, Bucharest, Romania, 022328S.C. Medisprof S.R.L, Cluj Napoca, Romania, 400641Institutul Oncologic, Prof. Dr. I. Chiricuta Cluj-Napoca, Cluj-Napoca, Romania, 400015Spitalul Clinic Judetean de Urgenta ,,Sf. Apostol Andrei” Constanta, Clinica Oncologie Medicala, Constanţa, Romania, 900591S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala, Craiova, Romania, 200347SC Oncolab SRL, Oncologie, Craiova, Romania, 200385S.C. Oncocenter Oncologie Clinica S.R.L, Timisoara, Romania, 300166 |
| 3 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | In curs de recrutare | Site RO40002, Bucharest, RomaniaSite RO40009, Bucharest, RomaniaSite RO40005, Cluj-Napoca, RomaniaSite RO40007, Cluj-Napoca, RomaniaSite RO40004, Floresti, RomaniaSite RO40006, Iasi, RomaniaSite RO40008, Timisoara, RomaniaSite RO40010, Timisoara, Romania |
| 4 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Activ, inca nu se recruteaza | Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj Napoca, Cluj Napoca, Cluj, Romania, 400015S.C Radiotherapy Center Cluj S.R.L., Comuna Floresti, Cluj, Romania, 407280S.C Centrul de Oncologie Sf. Nectarie S.R.L, Craiova, Dolj, Romania, 200347Spital Lotus SRL, Ploiesti, Prahova, Romania, 100011S.C Oncocenter Oncologie Clinica S.R.L, Timisoara, Timis, Romania, 300210S.C Oncomed S.R.L, Timisoara, Timis, Romania, 300239S.C Oncopremium Team S.R.L , Baia Mare, Romania, 430291Institutul Clinic Fundeni, Bucuresti, Romania, 022328Spitalul Clinic Coltea, Bucuresti, Romania, 030171Hifu Terramed Conformal SRL, Bucuresti, Romania, 031864Institutul Regional de Oncologie Iasi, Iasi, Romania, 700483 |
| 5 | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma | In curs de recrutare | S.C Oncopremium Team S.R.L , Baia Mare, Romania, 430291S.C Gral Medical S.R.L, Bucuresti, Romania, 31422Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015Spitalul Clinic Judetean de Urgenta „Sf Apostol Andrei” Constanta, Constanta, Romania, 900591S.C Centrul de Oncologie Sf. Nectarie S.R.L, Craiova, Romania, 200347S.C Pelican Impex S.R.L, Oradea, Romania, 410469S.C Oncomed S.R.L, Timisoara, Romania, 300239 |
| 6 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) | Activ, inca nu se recruteaza | SC Oncopremium Team SRL, Baia Mare, Romania, 430295Fundeni Clinical Institute, Gastroenterology and Hepatology Clinic, Bucharest, Romania, 022328Focus Lab Plus SRL, Bucuresti, Romania, 021389Bendis Clinic Srl, Cluj-napoca, Romania, 400352Sf. Nectarie Oncology Center, Craiova, Romania, 200347S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania, 407280 |
| 7 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | In curs de recrutare | S.C. Radiotherapy Center Cluj S.R.L ( Site 0391) Recruiting Cluj-Napoca, Cluj, Romania, 407280 Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394) Recruiting Craiova, Dolj, Romania, 200347 Contact: Study Coordinator +40722161545 Centrul Medical Topmed ( Site 0398) Recruiting Targu-Mures, Mures, Romania, 540156 Contact: Study Coordinator +40740277907 |
| 8 | Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer | Activ, inca nu recruteaza | Med Life Bucuresti, Romania, 03748 Gral Medical Bucuresti, Romania, 31422 Medisprof Cluj-Napoca, Romania, 400641 Spitalul Clinic Judetean de Urgenta „Sf. Apostol Andrei” Constanta Constanţa, Romania, 900591 Oncolab Craiova, Romania, 200385 |
Cancere esofagiane
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) | Activ, inca nu se recruteaza | SC Oncopremium Team SRL, Baia Mare, Romania, 430295Fundeni Clinical Institute, Gastroenterology and Hepatology Clinic, Bucharest, Romania, 022328Focus Lab Plus SRL, Bucuresti, Romania, 021389Bendis Clinic Srl, Cluj-napoca, Romania, 400352Sf. Nectarie Oncology Center, Craiova, Romania, 200347S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania, 407280 |
| 2 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) | Activ, inca nu se recruteaza | Focus Lab Plus SRL, Bucuresti, Romania, 021389CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania, 400015Sf. Nectarie Oncology Center, Craiova, Romania, 200347County Emergency Hospital Suceava, Suceava, Romania, 720237 |
| 3 | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) | Activ, inca nu se recruteaza | S C Pelican Impex SRL ( Site 2403), Oradea, Bihor, Romania, 410469S.C. Radiotherapy Center Cluj S.R.L ( Site 2407), Comuna Floresti, Cluj, Romania, 407280S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2404), Craiova, Dolj, Romania, 200347S.C.Focus Lab Plus S.R.L ( Site 2401), Bucuresti, Sector 2, Romania, 021389S C Oncocenter Oncologie Medicala S R L ( Site 2405), Timisoara, Timis, Romania, 300166S.C.Gral Medical S.R.L ( Site 2406), Bucuresti, Romania, 031422Spitalul Clinic Judetean De Urgenta Constanta ( Site 2402), Constanta, Romania, 900591 |
| 4 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | In curs de recrutare | Institutul Oncologic „Prof.Dr.I.Chiricuta” Cluj Napoca, Cluj-Napoca, Cluj, Romania, 400015Radiotherapy Center Cluj, Floreşti, Cluj, Romania, 407280Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania, 200347Institutul Clinic Fundeni, Bucuresti, Romania, 022328Spitalul Clinic Coltea, Bucuresti, Romania, 030171Medisprof, Cluj-Napoca, Romania, 400641Centrul de Oncologie Euroclinic, Iaşi, Romania, 700106 |
| 5 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | In curs de recrutare | S.C. Radiotherapy Center Cluj S.R.L ( Site 0391) Recruiting Cluj-Napoca, Cluj, Romania, 407280 Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394) Recruiting Craiova, Dolj, Romania, 200347 Contact: Study Coordinator +40722161545 Centrul Medical Topmed ( Site 0398) Recruiting Targu-Mures, Mures, Romania, 540156 Contact: Study Coordinator +40740277907 |
Cancere de san
| Nr. Crt. | Nume | Status | Locatie |
| 1 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) | Activ, inca nu recruteaza | Centrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347 S.C. R.T.C. Radiology Therapeutic Center S.R.L. Otopeni, Ilfov, Romania, 075100 SC Oncopremium Team SRL Baia Mare, Maramureș, Romania, 430291 Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 Spitalul Clinic Filantropia Bucuresti, Romania, 011171 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca Cluj-Napoca, Romania, 400015 Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta Constanta, Romania, 900591 |
| 2 | Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) | In curs de recrutare | Local Institution Not yet recruiting Bucharest, Romania, 011171 Contact: Site 0029 Local Institution Not yet recruiting Bucuresti, Romania, 022328 Contact: Site 0025 Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0028 Local Institution Not yet recruiting Floresti, Romania, 407280 Contact: Site 0027 Local Institution Not yet recruiting Suceava, Romania, 720237 Contact: Site 0026 |
| 3 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1) | Activ, inca nu recruteaza | Novartis Investigative Site Floresti, Cluj, Romania, 407280 Novartis Investigative Site Bucuresti, Romania, 011171 Novartis Investigative Site Bucuresti, Romania, 030463 Novartis Investigative Site Craiova, Romania, 200347 Novartis Investigative Site Iasi, Romania, 700483 Novartis Investigative Site Timisoara, Romania, 300219 |
| 4 | A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA) | Activ, inca nu recruteaza | County Hospital Alba; Oncology Alba Iulia, Romania, 510073 „Filantropia” Clinical Hospital; Gynecological Oncology Bucharest, Romania, 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology Cluj-Napoca, Romania, 400006 Centrul de OncologieSfantulNectarie Craiova, Romania, 200347 Oncomed SRL Timisoara, Romania, 300239 |
| 5 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | Activ, inca nu recruteaza | S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948 Craiova, Dolj, Romania, 200347 lnstitutul Oncologic Trestiore /ID# 124943 Bucharest, Romania, 022328 Spitalul Clinic Judetean de Urgenta /ID# 124945 Cluj, Romania, 400006 Oncomed SRL /ID# 127598 Timisoara, Romania, 300239 |
| 6 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | In curs de recrutare | „Filantropia” Clinical Hospital; Gynecological Oncology Not yet recruiting Bucharest, Romania, 011191 Institute of Oncology „Prof. Dr. I. Chiricuta” Not yet recruiting Cluj-Napoca, Romania, 400015 Oncology Center Sf. Nectarie Not yet recruiting Craiova, Romania, 200347 Centrul de OncologieOncohelp Not yet recruiting Timisoara, Romania, 300239 |
| 7 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer | Activ, inca nu recruteaza | Center of Oncology Euroclinic Bucharest, Romania Oncology Center Sf Nectarie Caracal, Romania Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology Cluj-Napoca, Romania Oncology Institute „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania Oncology Center Oncolab Craiova Craiova, Romania |
| 8 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | Activ, inca nu recruteaza | Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Cluj Clinical County Hospital; Oncology Dept Cluj-Napoca, Romania, 400006 Regional Institute of Oncology Iasi Iasi, Romania, 700483 |
| 9 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Activ, inca nu recruteaza | Emergency University Bucharest Hospital; Oncology Department Bucharest, Romania, 050098 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Inst. Cluj-Napoca; Cancer Dept Cluj-Napoca, Romania, 400015 Euroclinic Center of Oncology SRL Iasi, Romania, 700106 |
| 10 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. | Activ, inca nu recruteaza | Research Site Braila, Romania, 810325 Research Site Craiova, Romania, 200347 Research Site Onesti, Romania, 601048 Research Site Timisoara, Romania, 300239 |
| 11 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | In curs de recrutare | „Filantropia” Clinical Hospital; Gynecological Oncology Recruiting Bucharest, Romania, 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Recruiting Bucuresti, Romania, 022328 Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; OncologieMedicala Recruiting Cluj Napoca, Romania, 400015 Centrul de OncologieSfantulNectarie Recruiting Craiova, Romania, 200347 |
| 12 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | Activ, inca nu recruteaza | Spitalul Clinic CF nr.2 Bucuresti Bucharest, Romania, 011464 Spitalul Municipal Ploiesti Ploiesti, Romania, 100337 SpitalulJudetean de Urgente „Sf. IoancelNou” Suceava, Romania, 720237 Spitalul Clinic JudeteanMures TgMures, Romania, 540142 |
| 13 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy | Activ, inca nu recruteaza | Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 Euroclinic Center of Oncology SRL Iasi, Romania, 700106 |
| 14 | PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer | Activ, inca nu recruteaza | Prof. Dr. I. Chiricuta Oncology Institute Cluj-Napoca, Romania Sf. Nectarie SRL Oncologie Medical Center Craiova, Romania Center of Oncology Euroclinic Iași, Romania |
| 15 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | Activ, inca nu recruteaza | Prof. Dr. I. Chiricuta Institute of Oncology Active, not recruiting Cluj Napoca, Romania, 400015 Centrul de OncologieSfantulNectarie Craiova, Romania, 200347 Active, not recruiting |
| 16 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | Activ, inca nu recruteaza | Research Site Bucharest, Romania, 013811 Research Site Bucuresti, Romania, 011171 Research Site Bucuresti, Romania, 030171 Research Site Cluj Napoca, Romania, 400015 Research Site Cluj-Napoca, Romania, 400015 |
| 17 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer | Activ, inca nu recruteaza | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician. |
| 18 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Activ, inca nu recruteaza | Novartis Investigative Site Bucharest, Romania, 050098 Novartis Investigative Site Bucuresti, Romania, 022328 Novartis Investigative Site Timisoara, Romania, 300239 |
| 19 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | Activ, inca nu recruteaza | Novartis Investigative Site Bucharest, Romania, 022328 Novartis Investigative Site Bucharest, Romania, 050098 Novartis Investigative Site Bucuresti, Romania, 022328 Novartis Investigative Site Cluj-Napoca, Romania, 400015 Novartis Investigative Site Iasi, Romania, 700106 |
| 20 | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | Activ, inca nu recruteaza | Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 |
| 21 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | Activ, inca nu recruteaza | Oncomed SRL Timisoara, Romania, 300239 |
| 22 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) | In curs de recrutare | Novartis Investigative Site Craiova, Dolj, Romania, 200347 Novartis Investigative Site Craiova, Dolj, Romania, 200535 Novartis Investigative Site Bucuresti, Romania, 010991 Novartis Investigative Site Bucuresti, Romania, 011171 Novartis Investigative Site Cluj-Napoca, Romania, 400124 Novartis Investigative Site Iasi, Romania, 700106 Novartis Investigative Site Timisoara, Romania, 300239 |
| 23 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | Inca nu recruteaza | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj, Romania, 400015 Contact: Principal Investigator Onco Clinic Consult SA Craiova, Dolj, Romania, 200103 Contact: Principal Investigator Centrul de Oncologie Sfantu Nectarie Craiova, Dolj, Romania, 200347 Contact: Principal Investigator Institutul Oncologic Bucuresti IOB Bucharest, Romania, 22328 Contact: Principal Investigator |
| 24 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | In curs de recrutare | Research Site Recruiting Bucharest, Romania, 022328 Research Site Recruiting Bucharest, Romania, 022338 Research Site Recruiting Bucharest, Romania, 030171 Research Site Recruiting Cluj Napoca, Romania, 400015 Research Site Recruiting Iasi, Romania, 700483 Research Site Recruiting Ploiesti, Romania, 100337 Research Site Recruiting Timisoara, Romania, 300239 |
Cancere de prostata
| Nr. Crt. | Nume | Status | Locatie |
| 1. | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | In curs de recrutare | Centrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347 Contact 40351401336 Principal Investigator: Michael Schenker S.C. R.T.C. Radiology Therapeutic Center S.R.L. Otopeni, Ilfov, Romania, 075100 Contact 40372744344 Principal Investigator: Elena Ciubotaru SC Gral Medical SRL Bucuresti, Romania, 031422 Contact 40213230000 Principal Investigator: Cristina Tiut Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta Constanta, Romania, 900591 Contact 40241662222 Principal Investigator: Laura Mazilu |
| 2. | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | In curs de recrutare | Local Institution Not yet recruiting Craiova, Dolj, Romania, 200347 Contact: Site 0052 Local Institution Not yet recruiting Bucharest, Romania, 022328 Contact: Site 0042 Local Institution Not yet recruiting Cluj Napoca, Romania, 400015 Contact: Site 0041 Local Institution Not yet recruiting Cluj Napoca, Romania, 400015 Contact: Site 0043 Local Institution Not yet recruiting Constanta, Romania, 900591 Contact: Site 0020 Local Institution Not yet recruiting Timisoara, Romania, 300239 Contact: Site 0035 |
| 3. | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | In curs de recrutare | Sf. Constantin Hospital; Oncology Completed Brasov, Romania, 500019 Prof. Dr. Th. Burghele Clin Urology Hosp Active, not recruiting Bucharest, Romania, 050659 Prof. Dr. I. Chiricuta Institute of Oncology Completed Cluj Napoca, Romania, 400015 Institute of Oncology „Prof. Dr. I. Chiricuta” Not yet recruiting Cluj-Napoca, Romania, 400015 ONCOMED – Medical Centre Completed Timisoara, Romania, 300239 Municipal Hosp Turdal; Oncology Completed Turda, Romania, 401103 |
| 4. | A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Activ, inca nu recruteaza | Site RO40008 Cluj-Napoca, Cluj, Romania Site RO40009 Cluj-Napoca, Cluj, Romania Site RO40002 Floresti, Cluj, Romania Site RO40011 Timisoara, Timis, Romania Site RO40007 Brasov, Romania Site RO40003 Bucharest, Romania Site RO40006 Bucharest, Romania |
| 5. | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | Activ, inca nu recruteaza | Bucuresti, Romania Cluj-Napoca, Romania Floresti, Romania Iasi, Romania Otopeni, Romania Ploiesti, Romania Sibiu, Romania TarguMures, Romania Timisoara, Romania |
| 6. | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer | Activ, inca nu recruteaza | Baia Mare, Romania Brasov, Romania Bucharest, Romania Cluj- Napoca, Romania TarguMures, Romania |
| 7. | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer | Activ, inca nu recruteaza | Bucuresti, Romania, 22328 Bucuresti, Romania, 41345 Bucuresti, Romania, 50659 Bucuresti, Romania, 75000 Cluj-Napoca, Romania, 400015 Craiova, Romania, 200385 Craiova, Romania, 200642 Oradea, Romania, 410159 Ploiesti, Romania, 100337 Targu-Mures, Romania, 540103 |
| 8. | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC | Activ, inca nu recruteaza | Bucharest, Romania Cluj Napoca, Romania Craiova, Romania TarguMures, Romania |
| 9. | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | Activ, inca nu recruteaza | Sc Radiotherapy Center Cluj SRL Cluj, Romania |
| 10. | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | Activ, inca nu recruteaza | Brasov, Romania Bucharest, Romania Bucuresti, Romania Cluj Napoca, Romania Iasi, Romania |
| 11 | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | Activ, inca nu recruteaza | Arensia Exploratory Medicine Bucharest, Romania, 21105 |
Cancere de col uterin
| Nr. Crt. | Nume | Status | Location |
| 1. | Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 – 4) | Activ, inca nu recruteaza | Teo Health S.A. – Spitalul Sf. Constantin Brasov, Romania, 500091 Spitalul Clinic Municipal „Gavril Curteanu” Oradea, Romania, 410469 Clinica de radioterapie Timisoara, Romania, 300041 |
Cancere cu punct de plecare neprecizat
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) | In curs de recrutare | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala, Cluj Napoca, Romania, 400015Centrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania, 700483Oncocenter Timisoara , Timişoara, Romania, 300166 |
Cancere colorectale
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy | Activ, inca nu se recruteaza | Institutul Oncologic „Prof Alexandru Trestioreanu” Busuresti Sectia Oncologie Medicala I, Bucuresti, Romania, 022328Spitalul Clinic „Fundeni” Departament Oncologie Medicala – Gastroenterologie, Bucuresti, Romania, 022328Spitalul Clinic „Coltea” Sectia Oncologie Medicala, Bucuresti, Romania, 030171Institutul Oncologic „Prof. Dr. I. Chiricuta” Cluj Napoca Oncologie Medical, Cluj-Napoca, Romania, 400015S.C Oncolab S.R.L Sectia Oncologie Medicala, Craiova, Romania, 200385Institutul Regional de Oncologie Iasi Clinica de Oncologie Medicala, Iaşi, Romania, 700483Spitalul Clinic Judetean de Urgenta Sibiu Sectia Oncologie Medicala, Sibiu, Romania, 550245S.C ONCOMED S.R.L Departament Oncologie Medicala, Timişoara, Romania, 300239 |
| 2 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic) | Activ, inca nu se recruteaza | Spitalul Clinic „Fundeni” Departament Oncologie Medicala – Gastroenterologie, Bucuresti, Romania, 022328Institutul Oncologic „Prof. Dr. I. Chiricuta” Cluj Napoca Oncologie Medicala, Cluj Napoca, Romania, 400015Institutul Regional de Oncologie Iasi Clinica de Oncologie Medicala, Iasi, Romania, 700483 |
| 3 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | In curs de recrutare | Local Institution, Brasov, Romania, 002200, Contact: Site 0168 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0076 Local Institution, Constanta, Romania, 900591, Contact: Site 0075 Local Institution, Craiova, Romania, 200347, Contact: Site 0081 Local Institution, Suceava, Romania, 720237, Contact: Site 0089 |
| 4 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | In curs de recrutare | Research Site Bucharest, Romania, 022328 Research Site Cluj-Napoca, Romania, 400015 Research Site Cluj-Napoca, Romania, 400124 Research Site Craiova, Romania, 200347 Research Site Iasi, Romania, 700483 Research Site Timisoara, Romania, 300239 |
Cancere cap si gat
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714) | Activ, inca nu se recruteaza | Centrul Medical Sanador, Bucharest, Romania, 010991CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania, 400015Sf. Nectarie Oncology Center, Craiova, Romania, 200347Institutul Regional de Oncologie Iasi, Iasi, Romania, 700483County Emergency Hospital Suceava, Suceava, Romania, 720237 |
| 2 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE) | Activ, inca nu se recruteaza | Research Site, Baia Mare, Romania, 430031Research Site, Brasov, Romania, 500152Research Site, Cluj-Napoca, Romania, 400015Research Site, Cluj, Romania, 400058Research Site, Craiova, Romania, 200347 |
| 3 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | Activ, inca nu se recruteaza | SC Medisprof SRL, Cluj-Napoca, Cluj, Romania, 400058Centrul de Oncologie Sf. Nectarie SRL, Craiova, Dolj, Romania, 200347SC Oncolab SRL, Craiova, Dolj, Romania, 200385S.C. ONCOCENTER Oncologie Clinica S.R.L., Timisoara, Timis, Romania, 300166Spitalul Clinic Judetean de Urgenta Sibiu, Clinica Oncologie Medicala, Sibiu, Romania, 550245 |
| 4 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL) | Activ, inca nu se recruteaza | Research Site, Suceava, Romania, 720237 |
| 5 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (IT-MATTERS) | Activ, inca nu se recruteaza | Regional Institute of Oncology IASI, Iasi, Romania, 700483Spital Clinic Judetean Mures. Targu Mures, Romania, 540072 |
| 6 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1) | Recruteaza | Research Site Not yet recruiting Constanta, Romania, 900591 Research Site Not yet recruiting Suceava, Romania, 720237 |
| 7 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-4) | Recruteaza | GSK Investigational Site Recruiting Bucuresti, Romania, 021389 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Ingrid Iordan GSK Investigational Site Recruiting Cluj Napoca, Romania, 400015 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Calin Ioan Cainap GSK Investigational Site Recruiting Craiova, Romania, 200347 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Michael Schenker GSK Investigational Site Recruiting Floresti, Romania, 407280 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Andrei Ungureanu GSK Investigational Site Recruiting Iasi, Romania, 700106 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Constantin Volovat GSK Investigational Site Recruiting Otopeni, Romania, 075100 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Elena Ciubotaru GSK Investigational Site Recruiting Suceava, Romania, 720284 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Doina Elena Ganea GSK Investigational Site Recruiting Targu Mures, Romania, 540156 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Ingrid Oana Mesinschi |
| 8 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) | Recruteaza | GSK Investigational Site Recruiting Brasov, Romania, 500283 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Mariana Sporis GSK Investigational Site Recruiting Bucuresti, Romania, 021389 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Ingrid Iordan GSK Investigational Site Recruiting Cluj Napoca, Romania, 400015 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Calin Ioan Cainap GSK Investigational Site Recruiting Cluj-Napoca, Romania, 400015 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Tudor Eliade Ciuleanu GSK Investigational Site Recruiting Constanta, Romania, 900591 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Laura Mazilu GSK Investigational Site Recruiting Craiova, Romania, 200347 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Michael Schenker GSK Investigational Site Recruiting Floresti, Romania, 407280 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Andrei Ungureanu GSK Investigational Site Recruiting Iasi, Romania, 700106 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Constantin Volovat GSK Investigational Site Recruiting Oradea, Romania, 410469 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Ioana Adriana Puscas GSK Investigational Site Recruiting Otopeni, Romania, 075100 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Elena Ciubotaru GSK Investigational Site Recruiting Satu Mare, Romania, 440055 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Loredana Ioana Aracs-Tamas GSK Investigational Site Recruiting Suceava, Romania, 720284 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Principal Investigator: Doina Elena Ganea |
02 Întâlnirile STOP Cancer – „Covid-19 vs Cancer?”
10 STRATEGII DE LUPTĂ ÎMPOTRIVA CANCERULUI
Adesea cancerul este descris drept o „bătălie” în care trebuie să lupți ca să supraviețuiești. Dar din moment ce această luptă nu este echitabilă, cum trebuie să te comporți, ce trebuie să faci pentru a supraviețui cancerului?
Continue readingEFECTELE SECUNDARE ALE CHIMIOTERAPIEI
Efectele chimioterapiei sunt diferite în functie de fiecare persoană în parte. Chimioterapia are scopul de a distruge celulele canceroase, din păcate însă, ea poate afecta și celulele sănătoase din organism. Impactul asupra celulelor sănătoase cauzează apariția efectelor secundare ale chimioterapiei.
Continue readingSEMNE ȘI SIMPTOME ALE CANCERULUI
Simptomele care apar în cancer diferă foarte mult în funcție de locația tumorii.
Continue reading